Bookmark
Forward
LRRK2-targeted Parkinson disease drug advances into phase III.
Nature reviews. Drug discovery 2023 JanSizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Katie Kingwell. LRRK2-targeted Parkinson disease drug advances into phase III. Nature reviews. Drug discovery. 2023 Jan;22(1):3-5
Mesh Tags
Substances
PMID: 36509915
View Full Text
